UCSF Investigates Regenerative Cellular Therapies Targeting Often Fatal COVID-19 ARDS

UCSF Investigates Regenerative Cellular Therapies Targeting Often Fatal COVID-19 ARDS

Researchers from the University of California, San Francisco (UCSF) launched a study back in January to investigate the regenerative powers of mesenchymal stem cells (MSCs) but at the onset of the COVID-19 and with the approval of regulators, the research team pivoted to investigate whether cells derived from deep within the human bone can ultimately aid patients with a severe form of SARS-CoV-2, the virus behind COVID-19—that is those afflicted with acute respiratory distress syndrome (ARDS). Led by Michael Matthay, MD, UCSF conducts an ongoing randomized, double blind clinical trial assessing the efficacy and safety of mesenchymal stem cells (MSCs) for patients with ARDS. The Phase 2 study, funded by the Department of Defense, the National Institutes of Health (NIH) and the California Institute of Regenerative Medicine (CIRM), targets 120 ARDS patients. These patients are in danger, in the ICU and on ventilators.

ARDS: A Very Dangerous Situation

Severe progression of COVID-19 can lead to ARDS, a dangerous condition with a mortality rate of 27 percent for mild cases and 45 percent for severe ones. One study referred to in the recent UCSF news suggests only a 25 percent surv...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee